MacroGenics Inc
MGNX1.500USD
-0.070-4.46%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
94.89MMarket Cap
LossP/E TTM
More Details of MacroGenics Inc Company
MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.
MacroGenics Inc Info
Ticker SymbolMGNX
Company nameMacroGenics Inc
IPO dateOct 10, 2013
CEORisser (Eric)
Number of employees341
Security typeOrdinary Share
Fiscal year-endOct 10
Address9704 Medical Center Drive
CityROCKVILLE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20850
Phone13012515172
Websitehttps://www.macrogenics.com/
Ticker SymbolMGNX
IPO dateOct 10, 2013
CEORisser (Eric)
Company Executives of MacroGenics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
111.00K
+909.09%
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
11.00K
+144.44%
Dr. Ezio Bonvini, M.D.
Dr. Ezio Bonvini, M.D.
Senior Vice President - Research, Chief Scientific Officer
Senior Vice President - Research, Chief Scientific Officer
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Mr. Eric Risser
Mr. Eric Risser
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Jeffrey Peters
Mr. Jeffrey Peters
Senior Vice President, General Counsel, Corporate Compliance Officer
Senior Vice President, General Counsel, Corporate Compliance Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. James Karrels
Mr. James Karrels
Chief Financial Officer, Senior Vice President, Corporate Secretary
Chief Financial Officer, Senior Vice President, Corporate Secretary
186.80K
--
Mr. William K. Heiden
Mr. William K. Heiden
Independent Chairman of the Board
Independent Chairman of the Board
111.00K
+909.09%
Mr. Edward (Ed) Hurwitz, J.D.
Mr. Edward (Ed) Hurwitz, J.D.
Independent Director
Independent Director
44.07K
+17.30%
Dr. Stephen L. Eck, M.D., Ph.D.
Dr. Stephen L. Eck, M.D., Ph.D.
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
29.38K
--
Mr. Thomas Spitznagel, Ph.D.
Mr. Thomas Spitznagel, Ph.D.
Senior Vice President - Technical Operations
Senior Vice President - Technical Operations
21.40K
+157.36%
Dr. Margaret A. Liu, M.D.
Dr. Margaret A. Liu, M.D.
Independent Director
Independent Director
11.00K
+144.44%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Bellevue Asset Management AG
15.68%
Armistice Capital LLC
9.42%
The Vanguard Group, Inc.
6.68%
Frazier Life Sciences Management, L.P.
5.02%
Acadian Asset Management LLC
3.98%
Other
59.22%
Shareholders
Shareholders
Proportion
Bellevue Asset Management AG
15.68%
Armistice Capital LLC
9.42%
The Vanguard Group, Inc.
6.68%
Frazier Life Sciences Management, L.P.
5.02%
Acadian Asset Management LLC
3.98%
Other
59.22%
Shareholder Types
Shareholders
Proportion
Investment Advisor
28.03%
Hedge Fund
19.73%
Investment Advisor/Hedge Fund
15.85%
Private Equity
5.02%
Research Firm
4.95%
Individual Investor
3.33%
Venture Capital
0.28%
Pension Fund
0.07%
Other
22.74%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
335
49.00M
77.52%
-23.04M
2025Q2
349
54.16M
85.84%
-24.12M
2025Q1
365
56.04M
88.82%
-21.64M
2024Q4
367
57.72M
91.98%
-20.16M
2024Q3
367
57.51M
91.64%
-21.39M
2024Q2
370
63.01M
100.47%
-16.59M
2024Q1
368
67.02M
107.12%
-8.36M
2023Q4
353
64.08M
103.25%
-12.72M
2023Q3
352
60.31M
97.24%
-15.19M
2023Q2
356
62.23M
100.48%
-18.91M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Bellevue Asset Management AG
9.92M
15.69%
-9.97K
-0.10%
Jun 30, 2025
Armistice Capital LLC
5.96M
9.43%
-336.00K
-5.34%
Jun 30, 2025
The Vanguard Group, Inc.
4.21M
6.67%
-212.88K
-4.81%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
3.18M
5.02%
--
--
Jun 30, 2025
Acadian Asset Management LLC
2.49M
3.94%
+183.05K
+7.93%
Jun 30, 2025
Millennium Management LLC
2.02M
3.19%
+291.61K
+16.91%
Jun 30, 2025
Wasatch Global Investors Inc
3.25M
5.14%
+774.00
+0.02%
Jun 30, 2025
Renaissance Technologies LLC
1.33M
2.1%
+174.22K
+15.12%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.74M
2.76%
-2.76M
-61.25%
Jun 30, 2025
Koenig (Scott)
1.43M
2.26%
+52.83K
+3.85%
Aug 13, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Direxion Daily S&P Biotech Bull 3X Shares
0%
State Street SPDR S&P Biotech ETF
0%
Humankind US Stock ETF
0%
Proshares Ultra Russell 2000
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.02%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
iShares Biotechnology ETF
Proportion0.01%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0%
State Street SPDR S&P Biotech ETF
Proportion0%
Humankind US Stock ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of MacroGenics Inc?
The top five shareholders of MacroGenics Inc are:
Bellevue Asset Management AG holds 9.92M shares, accounting for 15.69% of the total shares.
Armistice Capital LLC holds 5.96M shares, accounting for 9.43% of the total shares.
The Vanguard Group, Inc. holds 4.21M shares, accounting for 6.67% of the total shares.
Frazier Life Sciences Management, L.P. holds 3.18M shares, accounting for 5.02% of the total shares.
Acadian Asset Management LLC holds 2.49M shares, accounting for 3.94% of the total shares.
Bellevue Asset Management AG holds 9.92M shares, accounting for 15.69% of the total shares.
Armistice Capital LLC holds 5.96M shares, accounting for 9.43% of the total shares.
The Vanguard Group, Inc. holds 4.21M shares, accounting for 6.67% of the total shares.
Frazier Life Sciences Management, L.P. holds 3.18M shares, accounting for 5.02% of the total shares.
Acadian Asset Management LLC holds 2.49M shares, accounting for 3.94% of the total shares.
What are the top three shareholder types of MacroGenics Inc?
The top three shareholder types of MacroGenics Inc are:
Bellevue Asset Management AG
Armistice Capital LLC
The Vanguard Group, Inc.
Bellevue Asset Management AG
Armistice Capital LLC
The Vanguard Group, Inc.
How many institutions hold shares of MacroGenics Inc (MGNX)?
As of 2025Q3, 335 institutions hold shares of MacroGenics Inc, with a combined market value of approximately 49.00M, accounting for 77.52% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -8.32%.
What is the biggest source of revenue for MacroGenics Inc?
In --, the -- business generated the highest revenue for MacroGenics Inc, amounting to -- and accounting for --% of total revenue.
